Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Praziquantel Recombinant Mouse Monoclonal Antibody (2A11)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Praziquantel Antibody (MA566358) in SDS-PAGE
SDS-PAGE characterization of Praziquantel under reducing conditions. Lane M: Protein marker (kDa); Lane PZQ: Purified Praziquantel Recombinant Monoclonal (Product # MA566358). Praziquantel showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-433.
产品信息
MA566358
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
2A11
抗原
Conjugate of PZQ hapten and KLH.
偶联物
形式
Liquid
浓度
1.9 mg/mL
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
Praziquantel is a widely used antiparasitic drug primarily effective against Schistosoma infections. It functions by disrupting calcium ion homeostasis in parasitic worms, leading to paralysis and eventual death of the parasite. Despite its extensive use for over four decades, the precise molecular mechanism remains partially understood. Praziquantel is administered in large tablets due to the high therapeutic dose required, which poses challenges, particularly for pediatric patients. Recent research has focused on developing new crystalline polymorphs and delivery methods to improve bioavailability and patient compliance, potentially reducing the required dosage and enhancing therapeutic outcomes. These advancements aim to sustain drug release and mitigate rapid metabolism into inactive metabolites. The drug's efficacy, safety, and pharmacokinetics continue to be explored to optimize treatment protocols and expand its use across different demographics.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
